āshibio - Crunchbase Company Profile & Funding

Q: Where is āshibio's headquarters?

āshibio is located in Brisbane, California, United States.

Q: Who invested in āshibio?

āshibio has 4 investors including Agent Capital And MPM Capital.

Q: When was the last funding round for āshibio?

āshibio closed its last funding round on obfuscated from a Series A round.

Q: How much funding has āshibio raised to date?

āshibio has raised obfuscated.

Overview

āshibio

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About āshibio

CB Rank

42675

āshibio is a privately held biotechnology business exploring innovative therapies to treat bone and connective tissue ailments.

Founded

obfuscation

Private

Series A

Brisbane, California, United States

1-10

ashibio.com

Biotechnology

Medical Device

Therapeutics

Funding Rounds

Series A

OBF

obfuscation

Details

Operating Status

Active

Company Type

For Profit

About the Company

āshibio creates treatments for rare bone and connective tissue ailments, potentially preventing symptoms or slowing their course.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Andecaliximab

A monoclonal antibody that inhibits the MMP9 enzyme, aimed at treating fibrodysplasia ossificans progressiva (FOP) by reducing abnormal bone formation in soft tissues.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A
obfuscated obfuscation	Series A - āshibio	4	obfuscated obfuscation	MPM Capital	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Agent Capital	—	Series A - āshibio	Preston Noon
Agent Capital	—	Series A - āshibio	Preston Noon
Agent Capital	—	Series A - āshibio	Preston Noon
Agent Capital	—	Series A - āshibio	Preston Noon
Agent Capital	—	Series A - āshibio	Preston Noon